perrigo co. plc - PRGO
PRGO
Close Chg Chg %
13.96 -0.47 -3.33%
Closed Market
13.49
-0.47 (3.33%)
Volume: 2.96M
Last Updated:
Dec 4, 2025, 4:00 PM EDT
Company Overview: perrigo co. plc - PRGO
PRGO Key Data
| Open $13.99 | Day Range 13.34 - 14.07 |
| 52 Week Range 12.17 - 30.93 | Market Cap $1.92B |
| Shares Outstanding 137.62M | Public Float 136.85M |
| Beta 0.39 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.38 |
| Yield 852.31% | Dividend $0.29 |
| EX-DIVIDEND DATE Nov 28, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.59M |
PRGO Performance
| 1 Week | 1.05% | ||
| 1 Month | -6.58% | ||
| 3 Months | -40.44% | ||
| 1 Year | -51.94% | ||
| 5 Years | -72.95% |
PRGO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About perrigo co. plc - PRGO
Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
PRGO At a Glance
Perrigo Co. Plc
The Sharp Building
Dublin, Dublin 2/74
| Phone | 353-1-709-4000 | Revenue | 4.37B | |
| Industry | Pharmaceuticals: Major | Net Income | -171,800,000.00 | |
| Sector | Health Technology | Employees | 8,379 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PRGO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.808 |
| Price to Book Ratio | 0.812 |
| Price to Cash Flow Ratio | 9.73 |
| Enterprise Value to EBITDA | 10.518 |
| Enterprise Value to Sales | 1.549 |
| Total Debt to Enterprise Value | 0.561 |
PRGO Efficiency
| Revenue/Employee | 521,983.53 |
| Income Per Employee | -20,503.64 |
| Receivables Turnover | 6.374 |
| Total Asset Turnover | 0.428 |
PRGO Liquidity
| Current Ratio | 2.377 |
| Quick Ratio | 1.341 |
| Cash Ratio | 0.535 |
PRGO Profitability
| Gross Margin | 35.277 |
| Operating Margin | 7.273 |
| Pretax Margin | -1.845 |
| Net Margin | -3.928 |
| Return on Assets | -1.571 |
| Return on Equity | -3.537 |
| Return on Total Capital | -1.979 |
| Return on Invested Capital | -1.934 |
PRGO Capital Structure
| Total Debt to Total Equity | 87.968 |
| Total Debt to Total Capital | 46.80 |
| Total Debt to Total Assets | 39.385 |
| Long-Term Debt to Equity | 86.482 |
| Long-Term Debt to Total Capital | 46.009 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Perrigo Co. Plc - PRGO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.14B | 4.45B | 4.66B | 4.37B | |
Sales Growth
| -18.21% | +7.47% | +4.60% | -6.04% | |
Cost of Goods Sold (COGS) incl D&A
| 2.72B | 2.99B | 2.98B | 2.83B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 312.20M | 338.60M | 359.50M | 325.90M | |
Depreciation
| 102.20M | 86.20M | 93.70M | 97.40M | |
Amortization of Intangibles
| 210.00M | 252.40M | 265.80M | 228.50M | |
COGS Growth
| -16.24% | +9.82% | -0.51% | -4.87% | |
Gross Income
| 1.42B | 1.46B | 1.68B | 1.54B | |
Gross Income Growth
| -21.73% | +2.96% | +15.08% | -8.12% | |
Gross Profit Margin
| +34.23% | +32.79% | +36.07% | +35.28% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.19B | 1.29B | 1.40B | 1.22B | |
Research & Development
| 122.00M | 123.10M | 122.50M | 112.20M | |
Other SG&A
| 1.07B | 1.16B | 1.27B | 1.11B | |
SGA Growth
| -11.58% | +7.86% | +8.61% | -12.33% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 177.60M | 140.40M | 97.30M | 173.10M | |
EBIT after Unusual Expense
| 47.20M | 32.60M | 184.90M | 145.00M | |
Non Operating Income/Expense
| 332.00M | (26.40M) | 31.50M | 22.80M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| (1.10M) | (1.50M) | (1.90M) | (1.50M) | |
Interest Expense
| 120.50M | 145.30M | 224.70M | 248.50M | |
Interest Expense Growth
| -15.14% | +20.58% | +54.65% | +10.59% | |
Gross Interest Expense
| 120.50M | 145.30M | 224.70M | 248.50M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 258.70M | (139.10M) | (8.30M) | (80.70M) | |
Pretax Income Growth
| +273.16% | -153.77% | +94.03% | -872.29% | |
Pretax Margin
| +6.25% | -3.13% | -0.18% | -1.85% | |
Income Tax
| 389.60M | (8.20M) | (3.90M) | 80.00M | |
Income Tax - Current - Domestic
| 14.90M | (7.80M) | 18.20M | 30.40M | |
Income Tax - Current - Foreign
| 384.90M | 33.60M | 58.60M | 59.30M | |
Income Tax - Deferred - Domestic
| 3.30M | (8.60M) | (12.90M) | 27.60M | |
Income Tax - Deferred - Foreign
| (13.50M) | (25.40M) | (67.80M) | (37.30M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| (1.10M) | (1.50M) | (1.90M) | (1.50M) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (130.90M) | (130.90M) | (4.40M) | (160.70M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (130.90M) | (130.90M) | (4.40M) | (160.70M) | |
Net Income Growth
| - | +19.50% | +96.64% | -3,552.27% | |
Net Margin Growth
| -3.16% | -2.94% | -0.09% | -3.67% | |
Extraordinaries & Discontinued Operations
| 14.50M | (9.70M) | (8.30M) | (11.10M) | |
Discontinued Operations
| 14.50M | (9.70M) | (8.30M) | (11.10M) | |
Net Income After Extraordinaries
| (116.40M) | (140.60M) | (12.70M) | (171.80M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (116.40M) | (140.60M) | (12.70M) | (171.80M) | |
EPS (Basic)
| -0.8713 | -1.0454 | -0.0939 | -1.2504 | |
EPS (Basic) Growth
| +27.07% | -19.98% | +91.02% | -1,231.63% | |
Basic Shares Outstanding
| 133.60M | 134.50M | 135.30M | 137.40M | |
EPS (Diluted)
| -0.8713 | -1.0454 | -0.0939 | -1.2504 | |
EPS (Diluted) Growth
| +27.07% | -19.98% | +91.02% | -1,231.63% | |
Diluted Shares Outstanding
| 133.60M | 134.50M | 135.30M | 137.40M | |
EBITDA
| 537.00M | 511.60M | 641.70M | 644.00M | |
EBITDA Growth
| -36.59% | -4.73% | +25.43% | +0.36% | |
EBITDA Margin
| +12.97% | +11.50% | +13.78% | +14.72% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 31.667 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.813 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 2.845 | |
| Last Quarter’s Earnings | 0.80 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.57 | Next Fiscal Year Estimate | 2.925 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 2 | 4 | 4 |
| Mean Estimate | 0.81 | 0.67 | 2.85 | 2.93 |
| High Estimates | 0.83 | 0.69 | 3.00 | 3.15 |
| Low Estimate | 0.79 | 0.65 | 2.77 | 2.77 |
| Coefficient of Variance | 2.56 | 4.41 | 3.68 | 5.51 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Perrigo Co. Plc - PRGO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Perrigo Co. Plc - PRGO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Sep 10, 2025 | Charles Atkinson EVP, General Counsel & Sec. | 1,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $23.2 per share | 23,200.00 |
| Jul 11, 2025 | Roberto Khoury EVP and President of CSCI | 2,211 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2025 | Geoffrey M. Parker Director | 976 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2025 | Bradley A. Alford Director | 976 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Abbie Lennox EVP and CSO | 9,553 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 35,558 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 935,530.98 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 73,708 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,939,257.48 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 67,260 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,769,610.60 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 19,108 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 12,738 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 35,668 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 11,464 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 45,655 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,201,183.05 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 5,414 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 40,451 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,064,265.81 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 36,373 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 956,973.63 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 8,310 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 218,636.10 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 41,530 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,092,654.30 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 6,670 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 175,487.70 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 4,140 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |